Chemistry:Pemafibrate

Short description: Chemical compound

Pemafibrate

Clinical data
Trade names	Parmodia
Other names	K-13675
Routes of administration	Oral
ATC code	C10AB12 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (2R)-2-[3-({1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid
CAS Number	848259-27-8
ChemSpider	9700824
UNII	17VGG92R23
KEGG	D10711
ChEBI	CHEBI:228365
ChEMBL	ChEMBL247951
Chemical and physical data
Formula	C28H30N2O6
Molar mass	490.556 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@H](C(=O)O)Oc1cccc(c1)CN(CCCOc2ccc(cc2)OC)c3nc4ccccc4o3
InChI InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1 Key:ZHKNLJLMDFQVHJ-RUZDIDTESA-N

Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.

In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.